Yu Hong Li | Gastrointestinal Cancer | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Yu Hong Li  – Gastrointestinal Cancer – Best Researcher Award

Sun yat-sen University | China

      Profile

Scopus

Orcid

📍Current Position

Professor Yuhong Li holds dual roles as a Professor and Chief Physician at the prestigious Sun Yat-sen University Cancer Center. In her current capacity, she leads clinical teams, contributes to innovative research, and mentors the next generation of medical professionals. Her position underscores her influence in medical oncology and her commitment to enhancing cancer care globally.

 

📝Publication Achievements

Professor Li’s contributions to medical literature are both prolific and impactful, featuring studies that drive advancements in oncology: Her co-authored paper on capecitabine maintenance therapy for metastatic colorectal cancer provided significant insights into treatment optimization (Ann of Oncol, 2016). She has explored tumor resistance mechanisms via circulating tumor DNA monitoring, furthering the understanding of colorectal cancer progression (Drug Resist Updat, 2022). Her 2024 TRICE trial publication revolutionized conversion therapy approaches for colorectal liver metastases (Plos Medicine, 2024). Other key studies include innovations in adjuvant chemotherapy efficacy (Theranostics, 2021) and insights into resistance to targeted therapies (Clin Cancer Res, 2011).

 

🔍Ongoing Research

Professor Li’s current focus is on developing personalized treatment strategies for colorectal cancer liver metastases. By integrating clinical trials with translational research, she aims to bridge the gap between laboratory discoveries and patient care. Her dynamic use of circulating tumor DNA to monitor therapeutic resistance showcases her innovative methodologies.

 

🔬 Research Interests

Her research interests span: Gastrointestinal tumors including colorectal, pancreatic, and bile duct cancers. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The interplay of immune checkpoint inhibitors with genetic mutations in liver metastases.

 

🎓Academic Background

Bachelor’s Degree in Clinical Medicine, Bengbu Medical College (1986–1991). Master’s Degree in Oncology, Sun Yat-sen University (1994–1997). Doctorate in Oncology, Sun Yat-sen University (2000–2003). Her robust academic journey laid the foundation for her expertise in oncology.

 

🏆Scholarships and Awards

While specific accolades are not listed, her academic progression and professional trajectory reflect a history of recognition for excellence.

 

🧬Bioinformatics 

Professor Li integrates bioinformatics in her research, particularly for: Dynamic monitoring of circulating tumor DNA, enabling real-time insights into tumor response. Analyzing genetic resistance patterns to improve therapeutic accuracy.

 

🌐Professional Associations 

Professor Li is likely affiliated with leading oncology and gastroenterology societies, enhancing her collaborative impact.

 

 📚Training & Workshops 

She has completed multiple Good Clinical Practice (GCP) certifications (2001, 2006, 2007), demonstrating her dedication to ethical and high-standard clinical trials.

 

🎤Oral Presentations and🗣️Thought Leadership 

As an esteemed researcher, Professor Li frequently presents at national and international forums, sharing her findings and contributing to global oncology discussions.

 

🧑‍🔬Tasks Completed as a Researcher 

Design and execution of clinical trials for gastrointestinal cancer therapies. Translational research bridging laboratory innovations to clinical applications. Publication of high-impact papers, influencing clinical practices worldwide.

 

🚀Success Factors 

Her success is attributed to: Dedication to patient care and research excellence. The ability to collaborate across disciplines to innovate solutions. A focus on mentorship and education, ensuring sustainability in medical advancements.

 

🧪Publications & Laboratory Experience

With a portfolio of groundbreaking publications, Professor Li’s laboratory experience focuses on experimental designs that translate into actionable clinical strategies.

 

🔍 Conclusion

Professor Yuhong Li’s contributions to medical oncology position her as a global leader in cancer research. Her unwavering commitment to personalized care, innovative methodologies, and clinical excellence makes her an ideal candidate for any Best Researcher Award. Her efforts not only push the boundaries of science but also bring tangible improvements to patients’ lives worldwide.

📚Publications

Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma

           Author: Wang, F., Wang, Y., Ren, C., … Li, S., Guo, G.

          Journal: Pancreatology

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis

           Author: Li, Z.-J., Pat Fong, W., Zhang, D.-S., … Li, Y.-H., Wang, D.-S.

          Journal: npj Precision Oncology

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial

           Author: Wang, F., Jin, Y., Wang, M., … Zhao, Q., Xu, R.-H.

           Journal: Nature Medicine

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/ BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

           Author: Wang, D.-S., Ren, C., Li, S.-S., … Xu, R.-H., Li, Y.-H.

          Journal: PLoS Medicine

Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma

           Author: Sun, Y.-T., Lu, S.-X., Lai, M.-Y., … Yang, D.-J., Qiu, M.-Z.

          Journal: Cancer Immunology, Immunotherapy